Influenza
Conditions
Keywords
Influenza; vaccine; Seasonal influenza vaccine
Brief summary
This was an extensive, double-blind, randomized, placebo-controlled phase 3 study that aimed to evaluate the safety and immunogenicity of the seasonal inactivated, split virion, trivalent influenza vaccine (IVACFLU-S) in children from 6 months to under 18 years old and the elderly over 60 years old in Vietnam. The main target: Evaluating the safety of the single or double dose of seasonal influenza vaccine (IVACFLU-S) in Vietnamese children aged 6 months to 17 years and adults over 60 years old. Evaluating the immunogenicity of the seasonal inactivated, split virion, trivalent influenza vaccine (IVACFLU-S) after 1st injection on day 22 (+7) for groups ≥ 9 years old or day 49 (+7) for groups of 6 months to 8 years for each antigenic component of the vaccine.
Detailed description
The seasonal inactivated, split virion, trivalent influenza vaccine (TIV) were purified by the method of super centrifugation to create gradient segments in sucrose sugar produced by IVAC, or placebo produced by IVAC. Vaccines are produced on eggs, inactivated with formaldehyde. The dose of the vaccine tested was 15 mcg of HA for each antigen component in 0.5 ml. The influenza virus strains used to produce the 2020-2021 seasonal vaccine will also be provided by the NIBSC, which will be used according to WHO recommendations, which are expected to include the following Southern Hemisphere strains: Influenza A / H1N1 strain: Recombinant strain IVR-190 44250 E12 of the strain (A / Brisbane / 02/2018). Influenza strain A / H3N2: strain IVR-197 (H3N2) 44850 E14 recombinant strain (A / South Australia / 34/2019). Flu strain B (B / Washington / February 2019). Extensive phase 3 was conducted 2 sites: District Health Center (DHC) of Vu Thu, Thai Binh, Vietnam; and DHC of Binh Luc, Ha Nam. Subjects were from two age groups: 6 months-under 18 years and over 60 years. Both safety and immunogenicity were assessed
Interventions
BIOLOGICALIVACFLU-S
The Seasonal Inactivated, Split Virion, Trivalent Influenza Vaccine (TIV) were purified by the method of super centrifugation to create gradient segments in sucrose sugar produced by IVAC, or placebo produced by IVAC. Vaccines are produced on eggs, inactivated with formaldehyde. The dose of the vaccine tested was 15 mcg of HA for each antigen component in 0.5 ml. The influenza virus strains used to produce the 2020-2021 seasonal vaccine will also be provided by the NIBSC, which will be used according to WHO's recommendation, which is expected to include the following Southern Hemisphere strains: Influenza A / H1N1 strain: Recombinant strain IVR-190 44250 E12 of the strain (A / Brisbane / 02/2018). Influenza strain A / H3N2: strain IVR-197 (H3N2) 44850 E14 recombinant strain (A / South Australia / 34/2019). Flu strain B (B / Washington / February 2019).
Sponsors
Institute of Vaccines and Medical Biologicals, Vietnam
Vietstar Biomedical Research
Vietnam Military Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
6 Months to No maximum
Healthy volunteers
Yes
Inclusion criteria
\*Groups from 6 months to under 18 years: * Must have a sponsor (Father / Mother / Legal relative) and get the consent of the sponsor by signing a consent form to participate in the study. (Groups from 6 months to 8 years old must have a direct sponsor, groups 9-17 years old must have an indirect sponsor). * The sponsor must be able to read and write and must commit to taking the child or asking the child to visit on schedule. * If the Sponsor is not the child's parent, he/she must get the consent of the child's father/mother in writing. * Healthy or previous acute illness but stabilized within 2 weeks before injection. * No chronic disease (cancer, heart failure, kidney, liver ...) or chronic disease that has stabilized 3 months before injection. * Children under 1 year old: Must have gestational age ≥ 37 and ≤ 42 weeks at birth and birth weight\> 2500g and not have congenital disease. Children \<60 months of age are not severely malnourished (not exceeding I) Children 6 months to 8 years old who have never received a seasonal flu vaccine (from birth). * Female adolescents who are likely to become pregnant need to be informed of possible risks to the fetus if participating in the study and if participating in the study, must comply with contraceptive measures during the period. research. \*Group over 60 years old * Can read, write (self-report) and ready to sign the consent form to participate in research. * Ability to participate in scheduled visits and adhere to all procedures of testing. * Be healthy or have a stable medical condition through history exploitation and physical examination. For subjects who have medical problems or symptoms/signs, the medical problems or symptoms/signs must be consistently controlled or unchanged within the past 3 months. If you are using medication to treat that medical problem, the dose should be stable for at least 1 month before the product is injected. * For female subjects who are still fertile: Are not breastfeeding, or are not pregnant (based on a negative urine test) and are not planning to become pregnant until Day 22. For women who have not had sterilization surgery (hysterectomy or ligation fallopian tube) or menopause for less than a year must have a negative urine test and be ready to use effective contraception (intrauterine device, hormonal contraceptive, condom, vaginal diaphragm with spermicide) through visit Day 22
Exclusion criteria
* Currently (within 2 weeks from the time of selection) with severe acute illness with or without fever. * Participation in another therapy-related clinical trial within the past 3 months or plan to participate in a similar clinical trial at the same time it is. Use any other vaccine for 4 weeks prior to joining or refusing to delay vaccination of such vaccines until after the visit on Day 22 (for groups ≥ 9 years) or day 49 (with groups \<9 years old). * Having been vaccinated against influenza in the past 11 months (only children 6 months to 8 years old who have been previously vaccinated with influenza vaccine (from birth) are also
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects Experiencing Solicited Local and Systemic Adverse Events (AE) | Within 30 minutes of vaccination | Solicited local and systemic AEs were assessed by study staff 30 minutes after vaccination. |
| Number of Subjects Experiencing Unsolicited Adverse Events (AE) | within 21 days (age group 9-17 and older than 60 years) or 49 days (group 6 months to 8 years) after each vaccination | Unsolicited AEs were observed by study staff while the subject is at a clinic for a study visit or reported by the subject at any time. Any sign or symptom that would normally be considered a solicited AE (for example, fever, nausea, injection site pain) starting after 7 days post-vaccination was to be recorded as an unsolicited AE |
| Number of Subjects Experiencing Unsolicited Serious Adverse Events (SAE) | Day 1 to Day 91 | A serious adverse event (SAE) is defined as an AE that meets one of the following conditions: * Deadly. * Life-threatening. * Requires inpatient hospital admission or extended stay in hospital. * Causes birth defects. * Causes permanent or permanent injury or disability. * Critical medical events that may not be fatal, not life-threatening, or require inpatient treatment will be considered a SAE if it is judged by professional judgment that the incident would be potentially dangerous. subject's health and the need for medical or surgical intervention to prevent one of the aforementioned consequences |
| Number of Subjects With Seroconversion of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens, Overall and by Age Group | Day 22 (+7) for groups 9 years and above or 49 (+7) for groups of 6 months to under 9 years | Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI) Antibodies for Vaccine Antigens at Baseline and Day 22 or 49 after vaccination (depending on age group) for each antigenic component of the vaccine | Day 0, Day 22 and Day 49 | Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine |
| Geometric Mean Fold Change in HAI Antibody Titer, by Strain, Age Group, and Baseline Titer | Day 0, Day 22 and Day 49 | Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine |
| Number of Subjects With Hemagglutination Inhibition (HAI) Antibody tiers ≥ 1:40 for each antigenic component of the vaccine | Day 22 or 49 after vaccination ( depending on age group) | Serum specimens during Phase 3 were tested for the presence and titer of HAI antibodies to each one of the influenza strains represented in the vaccine |
Countries
Vietnam
Outcome results
None listed